Inovio Pharmaceuticals (NASDAQ:INO) Raised to Hold at Wall Street Zen

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other research firms have also recently commented on INO. Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th. HC Wainwright dropped their target price on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a report on Monday, June 1st. Finally, Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.25.

Inovio Pharmaceuticals Stock Performance

Shares of INO stock opened at $1.10 on Friday. The stock’s fifty day moving average price is $1.20 and its two-hundred day moving average price is $1.58. The company has a market cap of $90.50 million, a PE ratio of -0.76 and a beta of 1.49. Inovio Pharmaceuticals has a fifty-two week low of $1.03 and a fifty-two week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. On average, equities analysts predict that Inovio Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Focus Partners Wealth bought a new stake in shares of Inovio Pharmaceuticals during the third quarter worth about $33,000. Raymond James Financial Inc. grew its holdings in shares of Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 16,309 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Inovio Pharmaceuticals during the third quarter worth $41,000. Zacks Investment Management acquired a new position in shares of Inovio Pharmaceuticals during the third quarter worth $46,000. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 18,160 shares during the period. 26.79% of the stock is currently owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.